GRCE
Grace Therapeutics, Inc.
NASDAQ: GRCE · HEALTHCARE · BIOTECHNOLOGY
$2.35
-3.77% today
Updated 2026-06-05
Market cap
$35.59M
P/E ratio
—
P/S ratio
197.75x
EPS (TTM)
$-0.31
Dividend yield
—
52W range
$2 – $5
Volume
0.8M
Grace Therapeutics, Inc. (GRCE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-12.57%
ROA
-10.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2009 | — | $-922101.00 | — | — | — |
| 2010 | — | $-1.51M | — | — | — |
| 2011 | $29040.00 | $-3.08M | 100.00% | -10,980.25% | -10,591.92% |
| 2012 | $10475.00 | $-6.54M | 51.25% | -62,535.93% | -62,421.58% |
| 2013 | $707395.00 | $-6.73M | 43.89% | -963.79% | -951.73% |
| 2014 | $450159.00 | $-10.44M | 41.73% | -2,156.17% | -2,318.28% |
| 2015 | $300502.00 | $-1.32M | -849.81% | -3,296.73% | -440.18% |
| 2016 | $39197.00 | $-4.66M | -6,475.12% | -18,096.16% | -11,892.78% |
| 2017 | — | $-7.91M | — | — | — |
| 2018 | — | $-16.65M | — | — | — |
| 2019 | — | $-39.37M | — | — | — |
| 2020 | — | $-50.98M | — | — | — |
| 2021 | $309318.00 | $-31.05M | 61.22% | -8,377.05% | -10,039.81% |
| 2022 | $0.00 | $-12.27M | — | — | — |
| 2023 | $0.00 | $-57.39M | — | — | — |
| 2024 | $0.00 | $-17.44M | — | — | — |
| 2025 | $0.00 | $-13.63M | — | — | — |
Frequently asked questions
How much free cash flow does GRCE generate?
GRCE produced $-14.90M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is GRCE's balance sheet healthy?
GRCE holds $22.13M in cash and equivalents against — in long-term debt, on $66.61M of shareholder equity. That debt is best read against the cash flow the business throws off each year.